Scarica l'app Stockscreener
2.88
0.69%
-0.02
Dopo l'orario di chiusura:
2.94
0.06
+2.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Precedente Chiudi:
$2.90
Aprire:
$2.93
Volume 24 ore:
3.59M
Relative Volume:
1.42
Capitalizzazione di mercato:
$263.42M
Reddito:
-
Utile/perdita netta:
$-67.68M
Rapporto P/E:
-1.7349
EPS:
-1.66
Flusso di cassa netto:
$-54.24M
1 W Prestazione:
+1.05%
1M Prestazione:
+44.72%
6M Prestazione:
+166.67%
1 anno Prestazione:
-38.20%
Intervallo 1D:
$2.8247
$3.08
Intervallo di 1 settimana:
$2.2301
$3.1599
Portata 52W:
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
Nome
Cabaletta Bio Inc
Settore
Industria
Telefono
(267) 759-3100
Indirizzo
2929 ARCH STREET, PHILADELPHIA, PA
Confronta CABA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.88 | 264.33M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Ripresa | Jefferies | Buy |
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-02-05 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Iniziato | William Blair | Outperform |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | Stifel | Buy |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-07-18 | Iniziato | Guggenheim | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-01-08 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Iniziato | Cowen | Outperform |
| 2019-11-19 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
Cabaletta Bio Inc. stock chart pattern explainedWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com
Why Cabaletta Bio Inc. stock could rally in 2025Earnings Trend Report & Low Risk Entry Point Tips - newser.com
How Cabaletta Bio Inc. stock reacts to bond yieldsTrade Exit Summary & Community Consensus Trade Signals - newser.com
Using flow based indicators on Cabaletta Bio Inc.Trade Entry Summary & High Yield Equity Trading Tips - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsMarket Weekly Review & Weekly Chart Analysis and Trade Guides - newser.com
Measuring Cabaletta Bio Inc.’s beta against major indices2025 Price Momentum & Verified Trade Idea Suggestions - newser.com
Can Cabaletta Bio Inc. hit a new high this monthVolume Spike & Real-Time Stock Price Movement Reports - newser.com
Can Cabaletta Bio Inc. stock surprise with earnings upside2025 Earnings Impact & Weekly High Potential Stock Alerts - newser.com
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025 - MarketScreener
Cabaletta Bio (CABA) Names Steve Gavel as Chief Commercial Officer - GuruFocus
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant - The Manila Times
275,000-option inducement: Cabaletta names Steve Gavel CCO to lead rese-cel strategy; BLA due 2027 - Stock Titan
Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning - MyChesCo
Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN
Cabaletta Bio (CABA): Assessing Valuation After RESET-PV Trial Results Spark Investor Interest - Yahoo Finance
What candlestick patterns are forming on Cabaletta Bio Inc.2025 Dividend Review & Verified Entry Point Signals - newser.com
Tools to monitor Cabaletta Bio Inc. recovery probabilityEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Cabaletta Bio Inc. stock trendline breakdown2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com
Cabaletta Bio (NASDAQ:CABA) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC Wainwright - MarketBeat
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating By Investing.com - Investing.com Canada
Cabaletta Bio (CABA) Is Up 12.6% After CAR T Therapy Shows Early Success Without Preconditioning – Has the Bull Case Changed? - Yahoo Finance
Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews
Cabaletta Bio stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
HC Wainwright & Co. Reiterates Buy Rating for CABA with $16 Pric - GuruFocus
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating - Investing.com
Can Cabaletta Bio Inc. stock outperform in 2025 bull marketJuly 2025 Recap & Expert Curated Trade Ideas - newser.com
Will Cabaletta Bio Inc. benefit from macro trendsWeekly Trend Report & Smart Swing Trading Alerts - newser.com
Cabaletta Bio's (CABA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Cabaletta Bio (CABA) Shares Surge 30% After Promising Pemphigus Vulgaris Data - GuruFocus
Cabaletta Bio, Inc. Presents First Rese-cel Data with No Pre Conditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - MarketScreener
Cabaletta Bio (CABA) Reports Positive Initial Results from RESET-PV Trial - GuruFocus
Cabaletta Bio Inc reports new data from RESET-PV trial - MarketScreener
Cabaletta Bio Reports Promising Initial Data from RESET-PV Trial of Rese-cel in Pemphigus Vulgaris Without Preconditioning - Quiver Quantitative
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - The Manila Times
What the charts say about Cabaletta Bio Inc. today2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
Published on: 2025-10-09 01:46:57 - newser.com
Cabaletta Bio Inc Azioni (CABA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):